Additional file 2 of Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology

Additional file 2: Table S1. Master Table of clinicopathological characteristics of 3,115 patients with NSCLC sequenced at DFCI. Table S2. EGFRL858R/ex19del/ex20ins variants reported in patients with NSCLC sequenced at DFCI. Table S3. KRASG12C variants reported in patients with NSCLC sequenced at DFCI. Table S4. Exon 14 skipping mutations and/or amplifications in MET reported in patients with NSCLC sequenced at DFCI. Table S5. ALK fusions reported in patients with NSCLC sequenced at DFCI. Table S6. ROS1 fusions reported in patients with NSCLC sequenced at DFCI. Table S7. BRAFV600E variants reported in patients with NSCLC sequenced at DFCI. Table S8. RET fusions reported in patients with NSCLC sequenced at DFCI. Table S9. NTRK fusions reported in patients with NSCLC sequenced at DFCI. Table S10. Master Table of clinicopathological characteristics of 5,560 patients with NSCLC sequenced at one of three institutions (DCC, VICC, MSKCC). Table S11. Frequency of eight targetable alterations in DFCI LUAD patients by pack-year groups. Table S12. Comparison of targetable alteration frequencies in pack-year groups among patients with NSCLC at DFCI. Table S13. Distribution of targetable alterations by pack-year smoking history among patients with LUSC at DFCI. Table S14. Multivariable logistic regression model of eight targetable alterations, incorporating continental ancestry scores, age at diagnosis, smoking pack-year history, sex and histology DFCI cohort). Table S15. Comparison of KRASG12C mutation frequencies across continental ancestries (discovery cohort from DFCI) and self-reported racial groups (validation cohort from DCC, MSKCC, and VICC). Table S16. Multivariable logistic regression model of eight targetable alterations, incorporating sex and histology (validation cohort). Table S17. Tumor mutational burden and Ashkenazi Jewish ancestry assessment in TCGA LUAD and LUSC cohorts. Table S18. Multivariable logistic regression model of eight targetable alterations, incorporating Ashkenazi Jewish ancestry scores, age at diagnosis, smoking pack-year history, sex and histology.

附加文件2：
表S1：3115例在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌（non-small cell lung cancer, NSCLC）患者临床病理特征总表。
表S2：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的EGFR L858R/19号外显子缺失/20号外显子插入突变变异谱。
表S3：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的KRAS G12C突变变异谱。
表S4：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的MET基因14号外显子跳跃突变及/或扩增情况。
表S5：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的ALK融合基因变异。
表S6：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的ROS1融合基因变异。
表S7：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的BRAF V600E突变变异谱。
表S8：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的RET融合基因变异。
表S9：在丹娜法伯癌症研究院（Dana-Farber Cancer Institute, DFCI）接受测序的非小细胞肺癌患者中报告的NTRK融合基因变异。
表S10：在三家机构（DCC、VICC、MSKCC）之一接受测序的5560例非小细胞肺癌患者临床病理特征总表。
表S11：按吸烟包年分组的丹娜法伯癌症研究院肺腺癌（lung adenocarcinoma, LUAD）患者中8种可靶向治疗变异的发生频率。
表S12：丹娜法伯癌症研究院非小细胞肺癌患者中，不同吸烟包年组间可靶向治疗变异发生频率的对比分析。
表S13：丹娜法伯癌症研究院肺鳞状细胞癌（lung squamous cell carcinoma, LUSC）患者中，按吸烟包年吸烟史分组的可靶向治疗变异分布情况。
表S14：纳入人群血统得分、诊断年龄、吸烟包年史、性别及组织学类型的8种可靶向治疗变异多因素logistic回归模型（丹娜法伯癌症研究院队列）。
表S15：不同大陆人群血统（丹娜法伯癌症研究院发现队列）与自我报告种族群体（DCC、MSKCC及VICC验证队列）间KRAS G12C突变频率的对比分析。
表S16：纳入性别及组织学类型的8种可靶向治疗变异多因素logistic回归模型（验证队列）。
表S17：癌症基因组图谱（The Cancer Genome Atlas, TCGA）肺腺癌与肺鳞状细胞癌队列的肿瘤突变负荷及德系犹太血统评估。
表S18：纳入德系犹太血统得分、诊断年龄、吸烟包年史、性别及组织学类型的8种可靶向治疗变异多因素logistic回归模型。